Drug Approval | February 22, 2022
UK MHRA approves Marksans All in One oral solution
Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs
Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
The transaction as well as the open offer is expected to be completed by June this year.
Essential products manufactured by Sartorius, using Sü dpack polymer films made from Dow resins, support safe and effective vaccine production for global vaccine supply
According to the Indian Journal of Medical Research in 2018, the estimated prevalence of pre-diabetes in India is 14%, which means that one out of six Indians is pre-diabetic
Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants
Dr. Reddy’s, will focus its resources and capabilities on its key therapy spaces of gastroenterology, pain management, cold and flu, allergy, oncology, neurology, paediatrics and women’s health as the Russia and CIS region continues to be a strong performer for the company
To be marketed by Strides Pharma Inc. in the US market
The researchers are of the view that the new drug designing strategy demonstrated by them could also be adopted to treat retroviral infections.
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
Subscribe To Our Newsletter & Stay Updated
